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The karyotypic chaos exhibited by human epi-
thelial cancers complicates efforts to identify
mutations critical for malignant transformation.
Here we integrate complementary genomic
approaches to identify human oncogenes.
We show that activation of the ERK and phos-
phatidylinositol 3-kinase (PI3K) signaling path-
ways cooperate to transform human cells.
Using a library of activated kinases, we identify
several kinases that replace PI3K signaling and
render cells tumorigenic. Whole genome struc-
tural analyses reveal that one of these kinases,
IKBKE (IKK3), is amplified and overexpressed
in breast cancer cell lines and patient-derived
tumors. Suppression of IKK3 expression in
breast cancer cell lines that harbor IKBKE
amplifications induces cell death. IKK3 acti-
vates the nuclear factor-kappaB (NF-kB) path-
way in both cell lines and breast cancers.
These observations suggest a mechanism for
NF-kB activation in breast cancer, implicate
the NF-kB pathway as a downstream mediator
of PI3K, and provide a framework for
integrated genomic approaches in oncogene
discovery.INTRODUCTION
Nearly all epithelial malignancies exhibit numerous karyo-
typic abnormalities and abundant evidence of widespread
genetic alterations. This complexity of genome structure
complicates efforts to delineate the roles of these muta-
tions in cancer initiation and maintenance. However, the
recent development of several complementary experi-
mental approaches now provides the tools necessary to
systematically deconvolute the complexity of somatic
cancer genetics.
One experimental approach is to identify genes and
proteins that drive cellular transformation through the
construction of experimental models of cancer. Together
with increasingly sophisticated genetically engineered
murine cancer models, human cell-based systems
enable the examination of the roles of specific mutations
implicated in cell transformation. Recent work indicates
that a limited set of genetic changes suffice to transform
human cells (Hahn et al., 1999). Specifically, the coex-
pression of the telomerase catalytic subunit (hTERT),
the SV40 Large T (LT) and small t (ST) oncoproteins,
and an activated allele of H-RAS (H-RASV12) render
a wide range of human cells tumorigenic (Zhao et al.,
2004). These models have facilitated the identification
of candidate oncogenes and tumor suppressor genes
(Rowland et al., 2005; Westbrook et al., 2005). These
approaches facilitate the identification of genes that
have the potential to drive tumorigenesis but do notCell 129, 1065–1079, June 15, 2007 ª2007 Elsevier Inc. 1065
alone establish whether these genes truly play a role in
human cancer.
A second approach is to characterize the genomic alter-
ations seen in cancer specimens using increasingly pow-
erful tools to identify amplifications, deletions, karyotypic
rearrangements, and point mutations. Some recurrent
amplifications identified by genome scale approaches
such as high-density single-nucleotide polymorphism
(SNP) arrays and array comparative genomic hybridization
(aCGH) contain well-characterized oncogenes such as
EGFR (Zhao et al., 2005) and c-MYC (Morrison et al.,
2005). These observations suggest other regions recur-
rently amplified in human tumors contain other yet-to-
be-characterized oncogenes. Indeed, recent applications
of these technologies led to the identification of MITF,
c-IAP1, and YAP as human oncogenes (Garraway et al.,
2005; Zender et al., 2006). However, amplified regions
are often large, spanning several megabases to entire
chromosome arms. Therefore, functional tools are needed
to pinpoint specific genes that drive transformation tar-
geted by copy-number alterations.
A third approach is the systematic modulation of the
expression of genes encoded in regions of chromosomal
imbalance. Although such studies have previously
required painstaking gene-by-gene analyses, RNA inter-
ference (RNAi) now provides the means to define the func-
tional consequences of gene copy-number changes in
a rapid and comprehensive manner. Indeed, several large
RNAi libraries now exist and have been used to examine
the function of genes in a high-throughput manner (Berns
et al., 2004; Paddison et al., 2004), including those neces-
sary for cancer cell viability (Moffat et al., 2006; Ngo et al.,
2006).
In principle, it should be possible to integrate such
approaches to develop a framework to identify and vali-
date genes critical to cancer development. Here we
have applied such an integrative genomic approach to
the Ras signaling pathway. The Ras signaling pathway
plays a critical role in coupling inputs from cell-surface
receptors to intracellular signaling pathways. Mutations
of receptor tyrosine kinases such as EGFR (Lynch et al.,
2004; Paez et al., 2004), of Ras proteins themselves
(Downward, 2003) or of proteins in Ras effector pathways
including those regulated by Raf/ERK/MAPK (Davies
et al., 2002) or PI3K (Samuels et al., 2004) occur in most,
if not all, epithelial cancers. Using these integrated ap-
proaches, we identify a kinase oncogene, IKBKE, which
acts downstream of AKT and is amplified in a substantial
percentage of human breast tumors.
RESULTS
Contributions of Ras Effector Pathways to Human
Cell Transformation
We previously showed that immortalized human embry-
onic kidney (HEK) epithelial cells expressing hTERT, LT,
and ST (HA1E), are rendered tumorigenic by the introduc-
tion of H-RASV12 (Hahn et al., 1999). Activation of Ras1066 Cell 129, 1065–1079, June 15, 2007 ª2007 Elsevier Inc.stimulates many pathways including, but not limited to,
the MAPK, PI3K, and RALGDS pathways (Downward,
2003). However, it is likely that only a subset of these path-
ways participate directly in H-RASV12-induced transfor-
mation. Since activating mutations are found in several
members of the MAPK and PI3K pathways in many human
cancers, we reasoned that the coactivation of these two
pathways might replace H-RASV12 in transformation. To
test this hypothesis, we manipulated the MAPK and
PI3K pathways in HA1E cells.
To activate the PI3K pathway, we expressed one of
three mutant alleles: myristoylated (myr) and therefore
constitutively active alleles of PIK3CA p110a (Klippel
et al., 1996) (myr-110a) or AKT1 (myr-AKT) (Kohn et al.,
1996) or a short hairpin RNA (shRNA) targeting PTEN
(Boehm et al., 2005). To activate the MAPK pathway, we
expressed one of three mutant alleles: an activated allele
of CRAF (C-Raf 22W) (Stanton et al., 1989), the BRAFE600
allele (Davies et al., 2002), or a constitutively active
MEK1D218,D222 allele (MEKDD) (Brunet et al., 1994). Using
these reagents, we created 16 cell lines expressing all
possible combinations of these mutant alleles. We
confirmed that these cell lines stably expressed each of
these activated alleles either singly or in pairwise combi-
nations (data not shown) and analyzed the ability of these
cells to grow in an anchorage-independent (AI) manner or
to form tumors in immunodeficient animals (Table 1).
When introduced singly, none of these mutant alleles
promoted AI colony formation (Table 1). However, we
found that certain combinations of activated alleles
substituted for H-RASV12 to render these immortalized
HEK cells tumorigenic (Table 1). Specifically, we found
that activation of the MAPK pathway by either BRAFE600
or MEKDD expression together with activation of the
PI3K pathway by myr-AKT expression induced AI growth
indistinguishable from that induced by H-RASV12 (Table 1,
upper panel, and Figure 1). Surprisingly, while either
BRAFE600 or MEKDD cooperated with myr-AKT to induce
AI growth, only cells expressing the MEKDD + myr-AKT
combination induced tumor growth comparable to that
observed in cells expressing H-RASV12 (Table 1, lower
panel, and Figure 1). These observations indicated that
coactivation of specific members of the MAPK and PI3K
pathways suffices to replace H-RASV12 in human cell
transformation. In these HEK cells, coexpression of
MEKDD and myr-AKT most closely recapitulated the
tumorigenic phenotype induced by H-RASV12 (Figure 1).
Identification of Transforming Kinases
This approach not only identified specific combinations of
activated members of the MAPK and PI3K pathways that
replace H-RASV12 in HEK cell transformation but also
established an experimental platform to discover other
transforming genes. We extended this work by screening
a large collection of genes to identify those that substitute
for myr-AKT. Because phosphorylation plays a key role in
Ras signalling, we hypothesized that other kinases may
participate in PI3K-induced transformation.
Table 1. Dissection of H-RASV12 Signaling in Transformation
Anchorage-Independent Growth
Vector C-Raf 22W B-RafE600 MEKDD
Vector    ±
PTEN-shRNA  +  
myr-110a    +
myr-AKT ± + +++ +++
H-RASV12 +++ ND ND ND
Tumor Formation
Vector C-Raf 22W B-RafE600 MEKDD
Vector    
PTEN-shRNA    
myr-110a    ++
myr-AKT    +++
H-RASV12 +++ ND ND ND
Transformation of HEK cells expressing hTERT, the SV40ER plus the indicated constructs. Transformation was assessed by both
anchorage-independent growth (upper) and the capacity for tumor formation in immunodeficient mice (lower). Colony formation
was scored as follows: (): no colonies, (±): few microscopic (100–200 mm) colonies, (+): many microscopic colonies, (++): micro-
scopic- and small macroscopic (200 mm–1 mm) colonies, (+++): small macroscopic and large macroscopic (>1 mm) colonies.
Tumors (3 injections per cell line) were scored as follows: (–): no tumors, (+): single tumor >8 week latency, (++): single tumor <8
week latency or multiple tumors >8 week latency, (+++): multiple tumors <8 week latency. ND, not determined.To identify such kinases, we created a library of 354
human kinases and kinase-related open reading frames
(ORFs), including 256 kinases (Table S1), cloned into
Gateway-compatible entry vectors (Rual et al., 2004).
Because membrane recruitment via the addition of a
myr sequence activates both the PI3K p110a subunit
and AKT (Klippel et al., 1996; Kohn et al., 1996), we cre-
ated a Gateway-compatible retroviral destination vector,
pWN-MF-DEST, which adds a myr sequence and
a FLAG-epitope tag (MF) to each introduced ORF. We
Figure 1. Activated MEK1 and AKT1 Cooperate to Replace
H-RASV12
AI microscopic (100–200 mm, gray), macroscopic (>200 mm, black)
colonies, and tumor formation (number of tumors formed/tumor sites
injected) are shown for HEK cells expressing hTERT, LT, ST, and the
indicated genes. Error bars represent mean ±SD for three independent
experiments.confirmed that this destination vector and myr tag were
functional (Figure S1). We then transferred each ORF
individually into pWN-MF-DEST (Figure 2A).
Using this library of 354 myr ORFs, we performed
a screen for genes that could replace myr-AKT and induce
transformation. We introduced pools consisting of 10–12
unique ORFs into immortal but nontumorigenic HEK cells
expressing MEKDD (HA1E-M). Several pools reproducibly
induced colony formation more than two standard devia-
tions greater than the median number of colonies
(Figure 2B). To determine the identity of the kinases in
these pools responsible for AI growth, we then created
cell lines expressing individual kinases from each of
such pools (Figure 2C). Of the four pools analyzed in this
manner, three contained one transforming kinase gene
and one pool contained two transforming kinase genes.
Each of these kinase genes (AKT1, IKBKE, DAK, TSSK6,
and CSNK1E) also induced tumor formation (Figure 2D
and data not shown). Since we had previously shown
that myr-AKT cooperates with MEKDD to transform these
immortalized cells, the identification of AKT1 validated
this screening approach. Thus, using a library of myr
kinases in retroviral vectors, we identified four kinases
that cooperate with activated MEK1 to replace
H-RASV12 in human cell transformation.
Amplification of IKBKE in Breast Cancer Cell Lines
and Patient-Derived Tumor Samples
Wenext explored whetherany of these kinasesare altered in
human cancers. First, we used high-density SNP arrays to
identify regions of copy-number gain or loss in 179 cell linesCell 129, 1065–1079, June 15, 2007 ª2007 Elsevier Inc. 1067
Figure 2. Identification of Oncogenes
Using a Myristoylated Kinase Library
(A) Experimental schema.
(B) AI growth of pools named by their plate num-
ber (1–5) and row (A–H). () and GFP indicate
the number of colonies produced by mock-
and GFP-vector- infected cells, respectively.
Black line and red dotted line indicate the me-
dian and 2 SD above the median, respectively.
(C) Identification of putative kinase oncogenes
from top scoring pools. Error bars indicate
mean ± SD for three independent experiments.
(D) Tumor formation by IKBKE in HA1E-M cells.
Tumorigenicity is indicated as the number of tu-
mors formed/number of tumor sites injected
and shown above the bars for each cell line.representing a wide spectrum of cancer types (Garraway
etal., 2005).We failed tofind clearevidenceofamplifications
of the loci encodingDAK,TSSK6, orCSNK1E in any of these
cell lines (data not shown). In contrast, we found copy-
number gain or amplification of 1q32 involving the IKBKE
locus in 8 of 49 (16.3%) breast cancer cell lines (Figure 3A).
Indeed, copy-number gain of 1q is the most common alter-
ation in breast cancers (Rennstam et al., 2003).
We next investigated whether IKBKE was similarly
amplified in primary human breast cancer specimens by
performing aCGH on 30 breast tumors representing differ-1068 Cell 129, 1065–1079, June 15, 2007 ª2007 Elsevier Incent clinicopathological stages (Yao et al., 2006). These
studies also revealed a region of recurrent copy-number
gain involving the IKBKE locus on chromosome 1q in 10
of 30 breast tumors (Figure 3B). We note that four of the
ten ductal carcinoma in situ (DCIS) cases analyzed
showed copy-number gain of IKBKE, suggesting that
amplification of this locus is an early event in the develop-
ment of some breast cancers. We failed to find an associ-
ation of IKBKE copy-number gain with estrogen receptor
or Her2/neu status or with the presence of lymph node in-
volvement at diagnosis. In addition, we sequenced the.
IKBKE gene in 28 breast tumors and 19 breast cancer cell
lines and failed to find evidence of somatic mutations, cor-
roborating other sequencing efforts (Bamford et al., 2004).
To confirm that the region of copy-number gain at 1q32
involves IKBKE, we performed fluorescence in situ hybrid-
ization (FISH) on several breast cancer cell lines and a
primary breast tumor containing an amplification of 1q32
(Figure 3C). We detected up to ten copies of IKBKE in
the UACC-812 and ZR-75-1 breast cancer cell lines and
five copies of IKBKE in MCF-7 cells. One of the DCIS
breast tumors, BWH-T18, harbored five copies of the
IKBKE locus in the majority of nuclei (Figure 3C).
We also investigated whether these DNA copy-number
changes corresponded to increases in IKBKE transcript
and protein levels. Indeed, serial analysis of gene expres-
sion (SAGE), quantitative RT-PCR, and immunoblotting
analyses confirmed that IKBKE (IKK3) is overexpressed
in cell lines and breast tumors that exhibited 1q32 gain,
suggesting that IKBKE is one target of this amplicon (Fig-
ures 3D and 3E and data not shown). In addition, we found
that an additional 13 of 17 cell lines (76.5%) and 10 of 21
breast cancers (47.6%) showed increased expression
(>2-fold) of IKBKE transcripts in the absence of 1q32
copy-number changes. Utilizing two different IKK3 anti-
bodies, the observed protein levels correlated with the
transcript levels (Figures 3D and 3E) and UACC-812 and
ZR-75-1 cells, which harbor 1q32 amplifications (Figures
3A and 3C), showed the highest levels of IKK3 of any cell
line analyzed (Figure 3E).
Although our initial experiments were performed in
immortalized HEK cells, we also found that the introduc-
tion of IKBKE transforms human mammary epithelial cells
(HMEC) expressing hTERT, the SV40ER, and MEKDD
(HMEC-M) (Figure 3F). In addition, since 1q32 amplifica-
tions result in increased levels of wild-type (WT) IKBKE,
we examined whether forced expression of the WT, non-
myr IKBKE allele also rendered cells tumorigenic. We
found that cells expressing WT IKBKE at levels found in
human cancer cells exhibited a similar capacity for tumor-
igenicity (Figures 2D and 3G), confirming that the allele
amplified in breast cancer specimens is transforming.
Together, these observations identified IKBKE as a trans-
forming kinase that is amplified and overexpressed in a
substantial fraction of breast cancer cell lines and primary
breast tumors.
Consequences of Suppressing IKBKE in Breast
Cancer Cells
The findings described above implicate IKBKE as breast
cancer oncogene. We next sought to explore whether
breast cancer cells are functionally dependent on IKBKE
expression. The unregulated expression of many onco-
genes renders cancer cells unusually dependent upon
the continued function of the oncogene for cell prolifera-
tion or viability. This property of oncogenes, termed
oncogene addiction, provides a rationale for targeting
oncogenes therapeutically. To determine whether the
presence of IKBKE amplifications and overexpressioninduces oncogene addiction, we examined the effects of
RNAi targeting IKBKE and other genes.
As part of a separate project to systematically discover
genes essential for cancer cell viability we have used the
shRNA library developed by the RNAi Consortium (TRC)
(Moffat et al., 2006) to screen a large collection of genes
required for the proliferation of cancer cell lines. As part
of this effort, we have screened the MCF-7 breast cancer
cell line with 6144 shRNA targeting 1200 genes, including
93% of the human kinome. The results from the screening
of MCF-7 cells are of particular relevance to the present
study, because this breast cancer cell line harbors
a 1q32 copy-number gain (Figures 3A and 3C) that results
in a modest 2.5-fold increase in IKBKE transcript levels
compared to immortalized MCF10A cells (Figure 3D).
Examining the data from this screen, we found that three
of five shRNA targeting IKBKE compromised cell prolifer-
ation and viability (Figures 4A, 4C, and 4D). We found that
the level of IKK3 suppression by these five shRNA corre-
lated with the observed decrease in cell proliferation and
viability in MCF-7 cells (Figures 4A, 4C, and 4D). These ob-
servations indicate that IKBKE is required for the prolifer-
ation and survival of MCF-7 breast cancer cells.
We note that this RNAi screen also included constructs
targeting three of the other four genes that emerged from
our gain-of-function screen (AKT1, CSNK1E, and TSSK6).
Similar to the results from shRNA targeting IKBKE we
observed that shRNA targeting AKT1 or CSNK1E also
inhibited MCF-7 cell proliferation (data not shown).
We next examined the data generated in the high-
throughput RNAi screen to determine whether any other
kinase encoded within the 1q32 amplicon was similarly
required for MCF-7 viability. We identified a minimally am-
plified region (5.6 Mb) containing IKBKE in the UACC-812
breast cancer cell line (Figure 3A). This minimally amplified
region contains nine additional kinase genes. However,
RNAi-mediated suppression of these other kinase genes
failed to induce a statistically significant decrease in viabil-
ity of MCF-7 cells (Figure 4B). We note that three of four
shRNA targeting NUAK2 partially inhibited the prolifera-
tion of MCF-7 cells but failed to satisfy the criteria em-
ployed to classify significantly decreased proliferation in
our high-throughput RNAi screen (See Experimental Pro-
cedures). Although these observations do not eliminate
the possibility that other genes within this 1q32 amplicon
may cooperate with IKBKE to induce transformation,
these findings suggest that IKBKE is a key target of the
1q32 amplification in breast cancer cell lines and tumors.
To confirm that these observations in MCF-7 cells ap-
plied to other breast cancer cell lines that show IKBKE am-
plifications, we next examined the ZR-75-1 breast cancer
cell line, which exhibits high-level amplification of IKBKE
(Figures 3A and 3C) and found that inhibition of IKBKE
expression in this cell line also compromised viability
(Figure 4C). In contrast, shRNA-mediated suppression of
IKBKE failed to affect viability in PC3 prostate cancer cells,
hTERT-expressing HMECs, or the MCF10A.DCIS.com
breast cancer cell line, all of which do not harborCell 129, 1065–1079, June 15, 2007 ª2007 Elsevier Inc. 1069
Figure 3. IKBKE Is Amplified in Breast Cancer Cell Lines and Tumor Samples
(A) Analysis of the IKBKE locus by SNP arrays in 49 breast cancer cell lines. Colorgrams representing SNP copy number at 1q32 are shown. Red
indicates allelic gain, while blue denotes allelic loss.
(B) Clustering of aCGH data based on chromosome 1 copy-number gain of 30 breast primary tumors. Colored rectangles indicate tumor grade (red, high;
purple, intermediate; andblue, low grade) and lymph node (LN), estrogen receptor (ER), or HER2 status (red, positive; blue, negative; and gray, unknown).1070 Cell 129, 1065–1079, June 15, 2007 ª2007 Elsevier Inc.
amplifications of IKBKE (Figure 4C). Corroborating these
qualitative observations, we found that suppression of
IKBKE in MCF10A.DCIS.com or PC3 cancer cells induced
only a small increase in doubling time (9.1%–28.0%) over
11 days (Figure 4D), while suppression of IKBKE in MCF-7
and ZR-75-1 cells increased doubling time by 80.6%–
114.5% (Figure 4D). These observations suggested that
IKBKE is essential for proliferation in breast cancer cell
lines that show increased IKBKE copy number.
IKK3 is a member of a family of five distinct but closely
related proteins, the IkB kinase (IKK) family, consisting
of IKKa, IKKb, IKKg, IKK3, and TBK1. Since IKK3 function
partly overlaps with other IKKs (Fitzgerald et al., 2003; Pe-
ters et al., 2000; Sharma et al., 2003), we next determined
whether the proliferation of ZR-75-1, MCF-7, or PC3 cells
depended upon expression of any of the other IKK family
members. We introduced five shRNA targeting each of
these IKK family members into MCF-7, ZR-75-1, and
PC3 cells. We required more than one shRNA construct
targeting the gene to decrease proliferation (see Experi-
mental Procedures) and found that IKK3 was the only IKK
family member required for proliferation of ZR-75-1 cells,
while both IKK3 and TBK1 were required for the prolifera-
tion of MCF-7 cells (Figure S2). We note that suppression
of TBK1 but not IKK3 inhibited the proliferation of PC3 cells.
Together, these observations implicate IKBKE as an es-
sential oncogene in breast cancer cell lines harboring am-
plifications of 1q32 and are reminiscent of similar findings
made in cell lines harboring other oncogenes such as
BCR-ABL and EGFR, which also appear to render onco-
gene-expressing cells particularly dependent upon their
expression (Weinstein and Joe, 2006).
Consequences of IKBKE Amplification
and Overexpression
Recent work implicates IKBKE in the innate immune re-
sponse to viral infections, as it activates the interferon
pathway in part by stimulating the activity of the transcrip-
tion factor IRF3 (Fitzgerald et al., 2003; Sharma et al.,
2003). We tested whether cells expressing IKBKE dis-
played evidence of increased IRF3 transcriptional activity
and found a 3- to 5-fold activation of the IRF3-responsive
interferon-stimulated regulatory element (ISRE) of the
IFIT2 gene in HA1E-M cells expressing either the myr orWT allele of IKBKE (Figure S3A). HA1E-M and HMEC-M
cells expressing these IKBKE alleles also showed in-
creased transcription of two known interferon-responsive
genes, IFNB1 andCCL5 (encoding RANTES) (Figures S3B
and S3C).
To determine whether activation of interferon-respon-
sive promoters was required for transformation induced
by IKBKE, we introduced IRF3-specific shRNA constructs
into transformed HA1E-M cells expressing myr-IKBKE
(Figure S3D). The suppression of IRF3 failed to suppress
AI growth (Figure S3E). These observations suggested
that, although the physiologic function of IKBKE involves
activation of interferon responses, this activity of IKBKE
may not be essential for transformation.
IKBKE also has been reported to activate the NF-kB
pathway (Peters et al., 2000). Thus, we next determined
whether the transforming activity of IKBKE is mediated
by NF-kB. We examined whether the expression of IKBKE
destabilized the cytoplasmic pool of IkBa. HA1E-M cells
expressing myr-IKBKE displayed a 43% reduction in cyto-
plasmic IkBa compared to levels observed in cells
expressing a control vector (Figures 5A and 5B). More-
over, even when we overexpressed IkBa in these
IKBKE-expressing cells, we failed to observe increased
IkBa protein expression (Figure 5C), indicating that IKK3
effectively drives IkBa degradation. One consequence of
IkBa degradation is the translocation of NF-kB transcrip-
tion factors from the cytoplasm to the nucleus. Consistent
with this expectation, we found that HA1E-M cells
expressing myr-IKBKE displayed a 32% reduction in cyto-
plasmic NF-kB p50 (Figures 5A and 5B), and 71% of these
cells displayed nuclear NF-kB p50 compared to 8% in
cells harboring a control vector (Figures 5D and 5E).
We also tested whether overexpression of IKBKE
induced NF-kB transcriptional activity. HA1E-M cells ex-
pressing myr-IKBKE exhibited a 5-fold higher level of
NF-kB activity compared to cells expressing a control
vector, as assessed by measuring the activity of a syn-
thetic NF-kB reporter gene (Figure 5F). To confirm that
IKBKE activated the expression of endogenous NF-kB
target genes, we measured the expression levels of nine
NF-kB target genes in HA1E-M or HMEC-M cells express-
ing myr- or WT IKBKE, respectively. IKBKE induced in-
creased expression of all of these transcripts compared(C) FISH analysis of IKBKE amplification in UACC-812, ZR-75-1, and MCF-7 breast cancer cell lines and BWH-T18 primary breast tumor. Green signal
indicates hybridization using an IKBKE-specific BAC probe, while red color indicates hybridization using a chromosome 1 specific a satellite DNA probe
(left panels) or chromosome 1 painting probe (right panels).
(D) Quantitative RT-PCR analysis of IKBKE expression in breast cancer cell lines and patient samples. Carcinomas and cell lines are color-coded to in-
dicate presence of amplified 1q32 (blue, nonamplified and red, amplified). Asterisks (*) indicate patient samples with corresponding aCGH data in (B).
Raw valueswere normalized toRPL39 levels. Fold changes are referenced to valuesobtained with the normal sample with the highest IKBKEexpression,
N050702.
(E) Immunoblotting for IKK3. Using the K-14 anti-IKK3 antibody (Santa Cruz, CA), immunoblot in left panel compares breast cancer and immortalized
breast cell lines lacking IKBKE copy-number gain (MCF10A, MCF10A.DCIS.COM) to breast cancer cell lines with low levels of IKBKE (MCF-7, MDA-
MB-231) and the middle immunoblot compares breast cancer cell lines harboring different levels of IKBKE copy-number gain. The immunoblot on
the right was performed with a different anti-IKK3 antibody (Sigma C-terminal).
(F) AI growth of HMEC-M cells harboring either a control vector (vector) or myr-IKBKE. Bar represents 2 mm. Colony number reflects large macroscopic
colonies (>1 mm). Error bars represent mean ± standard deviation (SD) for three independent experiments.
(G) Immunblotting for IKK3 in the indicated breast cancer cell lines or HMEC-M cells expressing myr- or wild-type IKBKE.Cell 129, 1065–1079, June 15, 2007 ª2007 Elsevier Inc. 1071
Figure 4. IKBKE Is an Essential Kinase in Breast Cancer Cells
(A) IKBKE is essential for MCF-7 cell proliferation. Lower panels show IKK3 expression in MCF-7 cells expressing IKBKE-specific shRNAs or a control
shRNA targeting GFP (shGFP).
(B) Effects of suppressing kinase genes located at 1q32. MCF-7 cells were infected with shRNA constructs (five per gene) targeting ten kinases
(ETNK2, PIK3C2B, RIPK5, DYRK3, IKBKE, MAPKAPK2, PCTK3, PFKFB2, NUCKS1, and NUAK2) located at 1q32. Solid line represents the median
and dotted lines indicate 1 and 1.5 SD below the median. shRNA targeting IKBKE (red), NUAK2 (blue), PFKFB2 (yellow), and ETNK2 (black) or the
other genes (gray) are shown.
(C) Effects of IKK3 suppression on viability. Representative micrographs obtained five days after infection with the indicated shRNA are shown.
(D) Effects of IKK3 suppression on proliferation. Cells were plated on day 0 and infected with IKBKE shRNA 24 hr later and cumulative cell numbers
were determined for 11 days. The doubling time for each cell line was determined and then normalized to cells expressing a control, scrambled shRNA
(shScr). Expression of IKK3 is shown in lower panels for the indicated cell lines. Error bars represent mean ± SD for three independent experiments.1072 Cell 129, 1065–1079, June 15, 2007 ª2007 Elsevier Inc.
Figure 5. IKBKE Activates the NF-kB Pathway in Transformation Models
(A and B) Effects of IKK3 expression on IkBa stability. Cytoplasmic IkBa levels in HA1E-M cells and quantification.
(C) RT-PCR and immunoblot (WB) analysis of IkBa overexpression. MUT: IkBa super-repressor, wt: wt IkBa allele.
(D and E) Localization of NF-kB p50. The antibody used here detects both NF-kB p50 and the NF-kB p50 precursor (p105).
(F) NF-kB reporter activity in the indicated cell lines.
(G) Change in expression of selected NF-kB-regulated genes in HA1E-M cells harboring either a control vector () or myr-IKBKE (+).
(H) Change in expression of selected NF-kB-regulated genes in HMEC-M cells harboring either a control vector () or WT IKBKE (+).
(I) Analysis of cyclin D1 protein levels in HA1E cells expressing MEKDD and/or the indicated genes.
(J and K) Effects of expressing MUT IkBa on the doubling time (J) and AI growth (K) of HA1E-M cells expressing either myr-IKBKE or myr-AKT.
(L) Effects of suppressing IKBKE on AI growth of AKT-transformed cells. () indicates control cells. Error bars in (E)–(H) and (J)–(L) represent mean ±
SD for three independent experiments.Cell 129, 1065–1079, June 15, 2007 ª2007 Elsevier Inc. 1073
Figure 6. IKBKE Activates the NF-kB Pathway in Breast Cancer
(A) Downregulation of NF-kB target genes in ZR-75-1 breast cancer cells after IKBKE suppression as determined by quantitative RT-PCR.
(B and C) Relative expression of MMP9 (B) and BCL2 (C) in breast cancer cell lines that harbor (UACC-812, ZR-75-1, MCF-7) or lack (SUM52) IKK3
gain or amplification. UACC-812 cells do not express BCL2. Error bars in (A)–(C) represent mean ± SD for three independent experiments.
(D and E) Examination of IKK3 overexpression and NF-kB pathway activation in primary breast cancer specimens. In (D), representative IHC staining
and scoring were used to assess IKK3 and nuclear c-REL expression. 0, no staining; 1, low staining; 2, moderate staining; 3, high staining.
(E) Coexpression of IKK3 and nuclear c-REL. Each point represents one breast cancer specimen. The p value determined by Fisher’s exact test.to cells expressing a control vector (Figures 6G and 6H).
Since cyclin D1 is overexpressed in over 50% of breast
cancers (Bartkova et al., 1994), we examined whether
the observed increases in CCND1 mRNA levels corre-
sponded to increased cyclin D1 protein levels. Indeed,
both HA1E-M or HMEC-M cells expressing myr-IKBKE
showed substantially elevated levels of cyclin D1 (Fig-
ure 5I and data not shown). These data demonstrated
that IKBKE activates the NF-kB pathway in two epithelial
cell types.
To determine whether activation of the NF-kB pathway
is necessary for transformation induced by IKBKE, we
inhibited NF-kB activity in IKBKE-transformed HEK cells
by expressing a mutant (MUT) ‘‘super-repressor’’ allele
of IkBa harboring two amino acid substitutions (S32A/
S36A), which renders this MUT IkBa resistant to phos-
phorylation and degradation (Brown et al., 1995). Expres-
sion of MUT IkBa in IKBKE-transformed HEK cells
increased doubling times (Figure 5J) and suppressed AI
colony formation by 90.7% compared to cells infected
with a control vector (Figure 5K). In summary, these results
implicate the activation of the NF-kB pathway in IKBKE-
mediated cell transformation.
We initially identified IKBKE as a kinase that replaced
AKT in transformation (Figure 2A). Since AKT has also
been reported to activate the NF-kB pathway (Ozes1074 Cell 129, 1065–1079, June 15, 2007 ª2007 Elsevier Inc.et al., 1999; Romashkova and Makarov, 1999), we deter-
mined if the NF-kB pathway is similarly required for AKT-
dependent transformation. Introduction of the MUT IkBa
allele increased the doubling time of HEK cells trans-
formed by AKT (Figure 5J) and suppressed AI growth by
73.9% (Figure 5K). We next examined whether IKBKE con-
tributed to cell transformation induced by AKT. Indeed, we
found that suppression of IKBKE by two different shRNA
constructs increased doubling times by 20.0%–59.0%
and inhibited the capacity of AKT-transformed HEK to pro-
liferate and grow in an AI manner (Figure 5L and data not
shown). In aggregate, these observations implicate aber-
rant activation of the NF-kB pathway by IKBKE as a critical
step in cell transformation induced by AKT.
Finally, we determined whether IKBKE regulates the
NF-kB pathway in breast cancer cell lines and patient-
derived breast cancer tissue samples. We first examined
changes in NF-kB gene expression after IKBKE suppres-
sion in ZR-75-1 and MCF-7 breast cancer cells and found
that of the expression of two IKBKE-induced NF-kB regu-
lated genes, MMP9 and BCL2 (Figures 5G and 5H), de-
creased upon suppression of IKBKE (Figure 6A and data
not shown). Breast cancer cell lines harboring the 1q32
amplification showed increased expression of these
genes compared to a breast cancer cell line that lacks
IKK3 expression (SUM52; Figures 3E, right panel, 6B,
and 6C). We next confirmed that these observations in cell
lines also extended to primary breast cancer specimens.
Since IKK3 has recently been shown to induce nuclear
accumulation of the NF-kB family member c-REL (Harris
et al., 2006), we performed immunohistochemistry (IHC)
to detect IKK3 and c-REL in an independent set of 20
breast cancer tissue samples. We found that 7 of 20
(35%) of these breast cancer specimens showed
increased expression of IKK3 (Figures 6D and 6E), con-
firming our observations in the initial breast cancer spec-
imens (Figures 3B and 3D). In addition, we found that
seven of seven (100%) breast tumors that exhibited in-
creased IKK3 expression also displayed nuclear c-REL.
In contrast, c-REL was expressed at very low levels or
was predominantly located in the cytoplasm in 12 of 13
(92%) of breast tumors that do not exhibit increased
IKK3 expression (Figures 6D and 6E). This correlation be-
tween IKK3 expression and nuclear localization of c-REL
was statistically significant (p < 0.0084). Together, these
observations demonstrated that IKK3 activates the
NF-kB pathway in breast cancer.
DISCUSSION
Identification of IKBKE as a Human Breast
Cancer Oncogene
Mutations of proto-oncogenes and tumor suppressor
genes allow incipient cancer cells to escape the normal
mechanisms that regulate cell and tissue homeostasis.
In particular, kinase oncogenes play essential roles in
many, if not all, human cancers and therefore are particu-
larly attractive therapeutic targets. Indeed, several kinase
inhibitors are already in clinical use. Based on these exam-
ples, several properties identify oncogenes with particular
promise for clinical translation including clear evidence
that mutation, amplification, or translocation of the puta-
tive oncogene occurs in primary tumors and functional
confirmation that cancer cells exhibit an unusual depen-
dence upon the oncogene for viability or proliferation.
Here, we identify IKBKE as a human breast cancer
oncogene. IKBKE is amplified and overexpressed in a sig-
nificant percentage of human breast tumors. In addition,
IKBKE expression leads to cell transformation when over-
expressed in immortalized human cells at levels found in
breast cancer specimens, and cancer cell lines that ex-
hibit IKBKE copy-number gain or amplification require
IKK3 expression for viability. Together, these observations
strongly support the conclusion that amplifications of
IKBKE play an important role in the pathogenesis of a sub-
set of breast tumors and identify IKK3 as promising cancer
target.
IKBKE, NF-kB and Breast Cancer
Prior studies have shown that activation of the NF-kB
pathway occurs in a significant percentage of human can-
cers (Karin et al., 2002) and specifically in breast tumors
(Biswas et al., 2004; Sovak et al., 1997). Although mem-
bers of the NF-kB signaling pathway including IKBKB,CARD11, MALT1, and BCL10 are required for the survival
and proliferation of specific diffuse large B cell lymphoma
cell lines (Ngo et al., 2006), the mechanism responsible for
increased NF-kB activity in human breast tumors
remained undefined (Karin et al., 2002). By examining
breast cancer cell lines and breast cancer tissue speci-
mens, we found that overexpression of IKK3 activates
the NF-kB signaling pathway and that this activity is nec-
essary for the transforming potential of IKK3. Furthermore,
the observation that IKK3 expression strongly correlates
with nuclear localization of c-REL in primary breast cancer
specimens suggests that a significant fraction of NF-kB
activation in breast cancer is driven by aberrant expres-
sion of IKK3. These observations corroborate prior reports
that showed that IKK3 directly activates c-REL (Harris
et al., 2006) or other NF-kB family members (Adli and
Baldwin, 2006; Eddy et al., 2005) and that c-REL accumu-
lates in nuclei of breast cancer cells (Sovak et al., 1997).
Although IKK3 is a member of the IKK family, IKK3
phosphorylates only one of two serine residues in IkBa
necessary for ubiquitination and degradation of IkBa (Pe-
ters et al., 2000). Since IKK3 participates in the activation
of innate immune responses mediated by IRF3 and IRF7
(Fitzgerald et al., 2003; Sharma et al., 2003; Tenoever
et al., 2007), a key physiological function of IKK3 and the
closely related family member TBK1 is likely to be related
to innate immunity. More recently, theDrosophila IKK fam-
ily member most closely related to IKK3, called DMIKK3,
appears to play several roles in development including
activation of nonapoptotic caspase function by phosphor-
ylation of DIAP1 (Kuranaga et al., 2006), F actin assembly
(Oshima et al., 2006), and mRNA localization during
oogenesis (Shapiro and Anderson, 2006). Although the
MUT IkBa (super-repressor) construct blocked IKK3-
dependent AI growth, further work is necessary to deter-
mine whether other pathways regulated by IKK3 also con-
tribute to the tumorigenic phenotype in breast and other
cancers.
While several breast cancer cells required IKK3 for
survival, some cancer cells including PC3 cells appear
to depend upon the expression of TBK1 for proliferation.
Although we failed to observe amplifications involving
the TBK1 locus (data not shown), it remains possible
that these IKKs interact or functionally substitute for
each other since these two noncanonical IKK family mem-
bers share similar functions in other assays (Fitzgerald
et al., 2003; Sharma et al., 2003). A recent report identifies
TBK1 as a component of the RalB/Sec5 exocyst complex
and indicates that TBK1 is essential for H-RASV12-induced
transformation (Chien et al., 2006). Since several mem-
bers of the canonical NF-kB signaling pathway are altered
in human leukemia and lymphomas (Karin et al., 2002),
these findings indicate that NF-kB activation may occur
by distinct mechanisms in different tumor types.
We found that breast cancer cell lines harboring 1q32
amplification and expressing high levels of IKK3 exhibit
exquisite sensitivity to suppression of IKK3 expression.
In contrast, we observed that suppression of IKK3 in otherCell 129, 1065–1079, June 15, 2007 ª2007 Elsevier Inc. 1075
cancer cell lines lacking significant 1q32 amplifications
failed to affect viability and proliferation. We note, how-
ever, that a dominantly interfering IKBKE allele sup-
presses AI proliferation of a breast cancer cell line without
1q32 amplification (Hs 578T) (Eddy et al., 2005), and
IKBKE suppression in HeLa cells leads to apoptosis (Adli
and Baldwin, 2006; MacKeigan et al., 2005). Both Hs
587T and HeLa cells express elevated levels of IKK3
(Adli and Baldwin, 2006; Eddy et al., 2005). Since we found
that several breast tumors overexpress IKBKE yet lacked
amplifications (Figure 3D), these observations suggest
that other alterations beyond copy-number alterations
also lead to increased IKBKE expression and/or activity
in some cancer cell lines and tumors.
IKBKE Replaces AKT in Transformation
We found that IKBKE replaces AKT in transformation and
that AKT-driven cell transformation requires NF-kB activ-
ity and IKBKE. These observations implicate IKBKE and
the NF-kB pathway as a key effector pathway triggered
by AKT signaling in transformation. Although previous re-
ports demonstrated that AKT activation of NF-kB involves
direct activation of the canonical IKK complex (Ozes et al.,
1999; Romashkova and Makarov, 1999), our observations
suggest that in some cell types AKT and IKK3 are function-
ally related.
In addition to IKBKE, we identified three other kinases
(DAK, TSSK6, and CSNK1E) that replaced activated
AKT1 in an experimental model of human cell transforma-
tion. Further work may determine that DAK, TSSK6, or
CSNK1E are altered in human tumors. Furthermore, iden-
tifying genetic alterations that cooperate with IKBKE am-
plification in breast cancer may pinpoint other pathways
that synergize with this oncogene.
Dissection of Ras Signaling
To identify kinases that replace myr-AKT in human cell
transformation, we determined whether activation of the
PI3K and MAPK pathways would cooperate to replace
H-RASV12 in an experimental model of human cell trans-
formation. Previous studies using similar transformation
systems used three mutant H-RASV12 alleles that prefer-
entially activate the PI3K, MAPK, or RALGDS pathways
and identified an important role for the pathway regulated
by RALGDS in H-RASV12-induced AI growth in several
types of human cells (Hamad et al., 2002; Rangarajan
et al., 2004). However, the further activation of the
MAPK or PI3K pathway in these experiments was neces-
sary to permit such engineered cells to form tumors.
Although activated MEK and AKT alleles cooperated to
replace H-RASV12 in human cell transformation, we also
found that the expression of some activated alleles within
the PI3K and MAPK pathways failed to cooperate to in-
duce tumorigenic potential. For example, although either
BRAFE600 or MEKDD cooperated with myr-AKT to confer
AI growth, BRAFE600 failed to cooperate with myr-AKT to
promote tumor formation (Table 1). SinceBRAFmutations
have not yet been identified in renal cancer but are fre-1076 Cell 129, 1065–1079, June 15, 2007 ª2007 Elsevier Inc.quently observed in other malignancies such as mela-
noma, these observations are consistent with the view
that particular combinations of Ras effector pathway mu-
tations cooperate in specific cell types (Rangarajan et al.,
2004). Alternatively, since accumulating evidence sug-
gests that activation of specific Ras effector pathways
leads to feedback inhibition (Courtois-Cox et al., 2006),
these observations may reflect lineage-specific feedback
loops.
Functional Genomics and Integrating
Complementary Genomic Approaches
The development of methodologies to identify genetic al-
terations at genome scale promises to provide a compre-
hensive view of cancer-associated mutations. However,
a full appreciation of these genetic alterations will require
equally efficient high-throughput methods to assess the
functional consequences of these genetic changes and
to evaluate them as potential therapeutic targets. The de-
velopment of genome-scale libraries of RNAi reagents has
facilitated loss-of-function approaches in mammalian
cells that have identified candidate tumor-suppressor
genes (Kolfschoten et al., 2005; Westbrook et al., 2005).
In parallel to these loss-of-function approaches, candi-
date oncogenes have been identified using screening
tools such as cDNA libraries derived from cancer cells or
the use of viral integration to activate endogenous genes
(Dupuy et al., 2006; Peeper et al., 2002).
Here we have combined both gain-of-function and loss-
of-function approaches with whole-genome characteriza-
tion of genetic alterations in cancer cell lines and tumors.
This integrated approach permitted us both to identify
IKBKE as a breast cancer oncogene amplified in a signifi-
cant percentage of human breast tumors and to verify its
functional role in mammary cell transformation. Similarly,
other recent reports highlight the power of integrating
complementary genomic approaches to identify genes
associated with oncogenesis (Garraway et al., 2005; Zen-
der et al., 2006) and metastasis (Kim et al., 2006). To-
gether, these reports suggest a framework for compre-
hensive approaches to annotate structural and
functionally important genetic alterations essential for
cancer development while efficiently validating targets of
particular promise for clinical translation.
EXPERIMENTAL PROCEDURES
Cell Culture, Vectors, and Retroviral Infection
HEK cells (Hahn et al., 1999) and HMECs expressing hTERT (Elenbaas
et al., 2001) have been described. To introduce or suppress specific
genes, retroviral (pBabe, pWzl, and pMKO) (Boehm et al., 2005;
Morgenstern and Land, 1990) or lentiviral (pLKO) (Moffat et al., 2006)
vectors were used. Retroviruses and lentiviruses were generated as
described (Boehm et al., 2005; Moffat et al., 2006). Details regarding
cell-culture conditions and retroviral vector construction are described
in the Supplemental Experimental Procedures. Tumor specimens and
breast cancer cell lines were obtained as described (Yao et al., 2006).
Myristoylated Kinase Library
ORFs were cloned into Gateway-compatible pEntry vectors by per-
forming site-specific BP recombination reactions as described (Rual
et al., 2004). pWzl-Neo-Myr-Flag DEST (pWN-MF-DEST) was created
by inserting an N-terminal myr-FLAG tag and the Gateway-selectable
cassette into the pWzl-Neo retroviral vector. To create specific pWN-
MF-ORF vectors, site-specific LR recombination reactions were
performed individually as described (Rual et al., 2004).
AI Growth and Tumorigenicity Assays
Growth of cells in soft agar was determined by plating 5 3 104 cells in
triplicate in 0.4% (HEK) or 0.3% (HMEC) Noble agar. Colonies greater
than 100 mm in diameter were counted microscopically 8 weeks after
plating. Colonies greater than 200 nm in diameter were counted mac-
roscopically 8 weeks after plating. Tumor xenograft experiments were
performed as described (Boehm et al., 2005). Tumor injection sites
were monitored for 80 days for tumor formation.
Immunoblotting and PCR
Immunoblotting was performed as described (Boehm et al., 2005). The
following antibodies were used: anti-IKK3 K-14 (Santa Cruz, CA) (Fig-
ure 3) or anti-IKK3 c-terminal (Sigma) (Figures 3–6), anti-IkBa C-15
(Santa Cruz, CA), anti-NF-kB H-119 (Santa Cruz, CA), anti-MEK1/2
(Cell Signaling), anti-Cyclin D1 (Neomarkers), or anti-IRF3 (Santa
Cruz, CA). For RT-PCR, total RNA was isolated using TRIzol (Invitro-
gen). For quantitative RT-PCR, we used SYBR-Green (Applied Biosys-
tems). A list of primers may be found in Supplemental Experimental
Procedures.
IHC
Breast cancer tissue microarray slides (Biomax BR803) were immuno-
stained with anti-IKK3- C-terminal (1:250; Sigma) and anti-c-Rel C ter-
minus (1:200; Chemicon) antibodies using microwave-citrate antigen
retrieval followed by standard IHC staining procedures. Arrays were
scored in a blinded manner by a pathologist on a scale of 0–3.
Genome Structure Analyses
SNP array, aCGH, and SAGE data were collected and analyzed as
described (Garraway et al., 2005).
RNAi
To stably suppress IKBKE and other members of the IKK family we
used pLKO.1 lentiviral shRNA constructs generated by TRC (Moffat
et al., 2006). Lentiviral infections were performed as described (Moffat
et al., 2006). Cell Titer Glo (Promega) was used to measure viability 5
days after lentiviral infection. Z scores were calculated by normalizing
the viability score of each well to the plate mean viability score and
standard deviation (SD) of plate viability scores: Z = (X-m)/s, where
X = assay value (relative luminescence), m = mean plate viability score,
and s = SD of plate viability scores. Suppression of viability was de-
fined as the capacity for at least one shRNA to decrease viability
more than 1.5 SD below the mean Z score and at least one additional
shRNA targeting the same kinase to decrease viability more that 1 SD
below the mean Z score.
Supplemental Data
Supplemental Data include three figures, one table, and Supplemental
Experimental Procedures, and Supplemental References and can be
found with this article online at http://www.cell.com/cgi/content/full/
129/6/1065/DC1/.
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